Linda Mai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Linda Mai has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Aleisha Nielsen
Respiratory and Sleep Medicine, Perth Children's Hospital Perth Western Australia Australia
1 shared publicationAndrew C Wilson
Telethon Kids Institute, The Centre for Child Health Research, The University of Western Australia Perth Western Australia Australia
1 shared publicationAndrew Tai
Respiratory and Sleep Department Women's and Children's Hospital Adelaide South Australia Australia
1 shared publicationAntony R Lafferty
Department of Endocrinology and Diabetes Canberra Hospital Garran Australian Capital Territory Australia
1 shared publicationCatherine S Choong
Telethon Kids Institute, The Centre for Child Health Research, The University of Western Australia Perth Western Australia Australia
1 shared publicationCharles F Verge
Department of Endocrinology Sydney Children's Hospital Randwick New South Wales Australia
1 shared publication
Latest Publications
- Open Access
- 16 August 2021
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 58 (2) , 248-255
Sleep‐disordered breathing in Australian children with Prader‐Willi syndrome following initiation of growth hormone therapy
Aim: In children with Prader‐Willi syndrome (PWS), growth hormone (GH) improves height and body composition; however, may be associated with worsening sleep‐disordered breathing (SDB). Some studies have reported less SDB after GH initiation, but follow‐up with polysomnography is still advised in most clinical guidelines.Methods: This retrospective, multicentre study, included children with PWS treated with GH at seven PWS treatment centres in Australia over the last 18 years. A paired analysis comparing polysomnographic measures of central and obstructive SDB in the same child, before and after GH initiation was performed with Wilcoxon signed‐rank test. The proportion of children who developed moderate/severe obstructive sleep apnoea (OSA) was calculated with their binomial confidence intervals.Results: We included 112 patients with available paired data. The median age at start of GH was 1.9 years (range 0.1–13.5 years). Median obstructive apnoea hypopnoea index (AHI) at baseline was 0.43/h (range 0–32.9); 35% had an obstructive AHI above 1.0/h. Follow‐up polysomnography within 2 years after the start of GH was available in 94 children who did not receive OSA treatment. After GH initiation, there was no change in central AHI. The median obstructive AHI did not increase significantly (P = 0.13), but 12 children (13%, CI95% 7–21%) developed moderate/severe OSA, with clinical management implications.Conclusions: Our findings of a worsening of OSA severity in 13% of children with PWS support current advice to perform polysomnography after GH initiation. Early identification of worsening OSA may prevent severe sequelae in a subgroup of children.
- 16 August 2021
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 58 (2) , 248-255
Open AccessSleep‐disordered breathing in Australian children with Prader‐Willi syndrome following initiation of growth hormone therapy
Aim: In children with Prader‐Willi syndrome (PWS), growth hormone (GH) improves height and body composition; however, may be associated with worsening sleep‐disordered breathing (SDB). Some studies have reported less SDB after GH initiation, but follow‐up with polysomnography is still advised in most clinical guidelines.Methods: This retrospective, multicentre study, included children with PWS treated with GH at seven PWS treatment centres in Australia over the last 18 years. A paired analysis comparing polysomnographic measures of central and obstructive SDB in the same child, before and after GH initiation was performed with Wilcoxon signed‐rank test. The proportion of children who developed moderate/severe obstructive sleep apnoea (OSA) was calculated with their binomial confidence intervals.Results: We included 112 patients with available paired data. The median age at start of GH was 1.9 years (range 0.1–13.5 years). Median obstructive apnoea hypopnoea index (AHI) at baseline was 0.43/h (range 0–32.9); 35% had an obstructive AHI above 1.0/h. Follow‐up polysomnography within 2 years after the start of GH was available in 94 children who did not receive OSA treatment. After GH initiation, there was no change in central AHI. The median obstructive AHI did not increase significantly (P = 0.13), but 12 children (13%, CI95% 7–21%) developed moderate/severe OSA, with clinical management implications.Conclusions: Our findings of a worsening of OSA severity in 13% of children with PWS support current advice to perform polysomnography after GH initiation. Early identification of worsening OSA may prevent severe sequelae in a subgroup of children.